Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Contineum Therapeutics, Inc. (CTNM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. Contineum files current reports on Form 8-K to describe material events such as clinical data readouts, financing transactions, shareholder votes and trial design updates, alongside its other periodic SEC reports.
For CTNM, clinical development milestones are a recurring theme in its filings. Form 8-K reports have summarized topline data from the PIPE-307 Phase 2 VISTA trial in relapsing-remitting multiple sclerosis and positive topline data from the PIPE-791 Phase 1b PET trial assessing LPA1 receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. Another 8-K details the design of a 26-week, international, randomized, double-blind, placebo-controlled Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, including its primary efficacy measure based on change in forced vital capacity.
Filings also document capital markets activity. Contineum has reported entering into an underwriting agreement for an upsized public offering of its Class A common stock under a shelf registration statement on Form S-3, as well as prior at-the-market offerings. These disclosures outline the terms of offerings, estimated net proceeds and related exhibits such as underwriting agreements and legal opinions.
Investors can use this page to review CTNM’s governance and shareholder matters, including results of its annual meeting of stockholders reported on Form 8-K, where director elections and auditor ratification votes are recorded. With real-time updates from EDGAR and AI-powered summaries, this filings page helps readers quickly understand the key points in Contineum’s 8-Ks and related exhibits, while still allowing full-text access to the underlying SEC documents for deeper analysis.
Balyasny Asset Management and affiliates report a passive ownership stake in Contineum Therapeutics, Inc. Class A common stock. Through Atlas Diversified Master Fund, Ltd., they beneficially own 2,312,800 shares, representing 7.60% of the class, based on 30,446,111 shares outstanding as of December 12, 2025.
The reporting group includes Balyasny Asset Management L.P., GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Contineum.
Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and related share sale. On February 11, 2026, he exercised 400 stock options at an exercise price of $1.26 per share, receiving 400 shares of Class A common stock.
That same day, he sold 400 Class A common shares at $16.00 per share in an open-market transaction. After these trades, he directly owned 14,954 Class A shares and 128,017 stock options. The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on September 23, 2025, and that the stock options are fully vested and exercisable.
Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. exercised stock options and sold a small block of shares. On February 11, 2026, he exercised options for 400 shares of Class A common stock at $1.01 per share and then sold 400 shares at $16 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he directly owned 156,052 shares of Class A common stock and held 75,530 stock options, with an additional 6,842 shares held indirectly by his spouse.
CTNM insider Daniel Lorrain filed a notice to sell 16,050 shares of common stock. The shares are expected to be sold on 02/11/2026 through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $252,787.50 and 23,099,173 shares outstanding.
The 16,050 shares were acquired the same day via an exercise of stock options paid in cash. The filing also lists prior Rule 10b5‑1 sales of CTNM common stock by Lorrain over the past three months, each involving 4,170 shares with disclosed gross proceeds.
A shareholder of CTNM has filed a notice of intent to sell 7,500 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $118,125.00 and an approximate sale date of 02/11/2026. These shares are shown as being acquired on the same date by exercise of stock options for cash. The filing also notes total common shares outstanding of 23,099,173 for context.
Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. reported planned stock sales under a prearranged Rule 10b5-1 trading plan. On February 3, 2026, the insider sold 3,000 shares of Class A common stock at a weighted average price of $14.8229 and 1,170 shares at a weighted average price of $15.2451. The prices in each trade reflect multiple executions within disclosed ranges. After these transactions, the officer directly held 156,052 shares of Class A common stock and had an additional 6,842 shares reported as indirectly owned by a spouse.
An insider of CTNM has filed a notice of intent to sell shares. The filing covers 4,170 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $59,964.60 and 23,099,173 shares outstanding.
The shares were originally acquired as 4,170 restricted stock units from the issuer on May 9, 2017. The same account has sold 4,170 shares on December 23, 2025 for $51,009.11 and another 4,170 shares on January 5, 2026 for $43,543.06 under a Rule 10b5‑1 trading plan for Daniel Lorrain.
Contineum Therapeutics reported that its General Counsel and Corporate Secretary, John Stephen Healy, received a grant of stock options on January 30, 2026. The award covers 206,411 shares of Class A common stock at an exercise price of $14.26 per share.
The options were granted under the company’s 2024 Equity Incentive Plan and vest in equal monthly installments over 48 months, conditioned on Healy’s continued service with the company. Following this grant, he beneficially owns 206,411 stock options, held directly.
Contineum Therapeutics reported a new equity award for its Chief Financial Officer, Peter Slover. On 01/30/2026, he received a grant of stock options to buy 192,000 shares of Class A common stock at an exercise price of $14.26 per share under the company’s 2024 Equity Incentive Plan. These options vest in equal monthly installments over 48 months, conditioned on his continuous service, and he beneficially owns 192,000 derivative securities directly after the grant.
Contineum Therapeutics, Inc. granted CEO and President Carmine N. Stengone a stock option award on January 30, 2026 under its 2024 Equity Incentive Plan. The grant covers 445,000 stock options with an exercise price of $14.26 per share.
The options relate to Class A common stock and vest in equal monthly installments over 48 months, as long as Mr. Stengone continues in service. The options expire on January 29, 2036, and all 445,000 derivative securities are reported as directly owned following the grant.